{"classes":[{"categories":[{"measurements":[{"comment":"Could not be estimated due to the low number of events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"30.9"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"1.6"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"7.9"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG007","lowerLimit":"2.6","upperLimit":"NA","value":"7.1"},{"groupId":"OG008","value":"1.6"},{"comment":"Could not be estimated due to the low number of events.","groupId":"OG009","lowerLimit":"5.6","upperLimit":"NA","value":"8.3"},{"groupId":"OG010","lowerLimit":"4.9","upperLimit":"11.5","value":"7.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"1"},{"groupId":"OG009","value":"22"},{"groupId":"OG010","value":"23"}],"units":"Participants"}],"description":"DOR was defined as time from first response (PR or better) to timing of disease progression or death (due to any cause), whichever came first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).","id":"OG000","title":"RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG001","title":"RRMM Dose Escalation: GEN3014 2 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG002","title":"RRMM Dose Escalation: GEN3014 4 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG003","title":"RRMM Dose Escalation: GEN3014 8 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG004","title":"RRMM Dose Escalation: GEN3014 16 mg/kg"},{"description":"Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.","id":"OG005","title":"RRMM Dose Escalation: GEN3014 24 mg/kg"},{"description":"Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.","id":"OG006","title":"R/R AML Dose Escalation: GEN3014 Dose Level 1"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG007","title":"RRMM Expansion Part A: GEN3014"},{"description":"Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.","id":"OG008","title":"R/R DLBCL Expansion Part A: GEN3014"},{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG009","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG010","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"MEDIAN","populationDescription":"Full Analysis set=all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed=participants evaluable for the outcome measure with a response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Dose Escalation, Expansion Part A and Expansion Part B: Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}